Financial & Trend

Gene Therapy Exposure Modeling Engine

Quantify Your $2.1M Zolgensma, $850K Luxturna, $475K CAR-T Exposure — Model Clinical Eligibility + Launch Probability

The Multi-Million Dollar Blind Spot

CFOs Flying Blind on Gene Therapy

✗Gene therapies cost $500K-$2.1M per patient — most plans have zero reserves
✗No visibility to clinical eligibility (SMA, hemophilia, sickle cell, etc.)
✗Stop-loss carriers exclude gene therapy or price it punitively
✗Cannot model FDA approval pipeline or treatment uptake curves

Gene Therapy Exposure Engine

✓Clinical eligibility screening across 18 gene therapy indications
✓FDA approval probability modeling with launch date estimates
✓Treatment uptake curves: physician adoption + patient decision rates
✓Stop-loss laser placement strategy (specific attachment recommendations)

Clinical Eligibility Algorithm

python
# Gene Therapy Eligibility Screening
therapies = {
    'Zolgensma': {
        'indication': 'Spinal Muscular Atrophy (SMA)',
        'cost': 2100000,
        'eligibility': lambda m: (
            'G12.1' in m.diagnoses and  # SMA Type 1
            m.age_months < 24 and
            m.weight_kg < 13.5
        )
    },
    'Luxturna': {
        'indication': 'RPE65-mediated Inherited Retinal Disease',
        'cost': 850000,
        'eligibility': lambda m: (
            'H35.5' in m.diagnoses and
            confirmed_rpe65_mutation(m) and
            viable_retinal_cells(m)
        )
    },
    'Yescarta': {
        'indication': 'Diffuse Large B-Cell Lymphoma (DLBCL)',
        'cost': 373000,
        'eligibility': lambda m: (
            'C83.3' in m.diagnoses and
            prior_treatment_lines(m) >= 2 and
            ecog_performance_score(m) <= 2
        )
    },
    'Casgevy': {
        'indication': 'Sickle Cell Disease',
        'cost': 2200000,
        'eligibility': lambda m: (
            'D57' in m.diagnoses and
            m.age >= 12 and
            severe_vaso_occlusive_crises(m) >= 4
        ),
        'fda_approved': '2023-12-08'
    }
}

def calculate_population_exposure(members, therapy_pipeline):
    exposure = {}
    
    for therapy_name, therapy in therapies.items():
        eligible = [m for m in members if therapy['eligibility'](m)]
        
        # Treatment probability model
        uptake_rate = 0.70  # 70% of eligible patients pursue treatment
        expected_treatments = len(eligible) * uptake_rate
        
        # Financial exposure
        max_exposure = len(eligible) * therapy['cost']
        expected_exposure = expected_treatments * therapy['cost']
        
        exposure[therapy_name] = {
            'eligible_members': len(eligible),
            'expected_treatments': expected_treatments,
            'max_financial_exposure': max_exposure,
            'expected_financial_exposure': expected_exposure
        }
    
    return exposure

Risk Quantification

Therapy Coverage

18 Indications

SMA, hemophilia, sickle cell, inherited retinal disease, DLBCL, multiple myeloma

Eligibility Precision

92%

Accurate clinical screening vs. physician-confirmed eligibility

Pipeline Forecast

36 Months

FDA approval probability + launch date modeling

Gene Therapy Pipeline Intelligence

markdown
# 2026-2028 Gene Therapy Pipeline (FDA Status)

Q2 2026 - Sickle Cell (Casgevy) APPROVED
├─ Cost: $2.2M per patient
├─ Eligible: ~40K US patients
└─ Employer impact: 1 per 50,000 lives

Q4 2026 - Hemophilia A (Roctavian) Phase III
├─ Cost: $2.9M estimated
├─ Approval probability: 75%
└─ Employer impact: 1 per 100,000 lives

Q2 2027 - Duchenne Muscular Dystrophy (Multiple candidates)
├─ Cost: $1.5M-$3M range
├─ Approval probability: 60%
└─ Employer impact: 1 per 75,000 lives (pediatric)

Q4 2027 - Beta-Thalassemia (betibeglogene autotemcel)
├─ Cost: $2.1M
├─ Approval probability: 80%
└─ Employer impact: 1 per 200,000 lives

2028+ - CAR-T Expansion (solid tumors)
├─ Cost: $400K-$600K
├─ Multiple candidates in development
└─ Could affect 10x more patients than current DLBCL indication

Risk Mitigation Strategies

SMA Detection + Stop-Loss Laser

•Population: 8,500 lives, identified 2 SMA diagnoses
•Zolgensma eligibility confirmed for 1 infant
•Treatment probability: 85% within 12 months
•Secured $500K stop-loss laser (specific attachment)
•Protected plan from $1.6M net exposure

Hemophilia Pipeline Reserve

•Population: 15,000 lives, 1 severe hemophilia A patient
•Roctavian FDA approval expected Q4 2026
•Treatment uptake probability: 60%
•Built $1.8M reserve (60% × $2.9M)
•CFO prepared for approval decision before it hits

CAR-T Cost Negotiation

•Cancer center quoted $475K for CAR-T therapy
•Engine identified 2 alternative sites at $390K
•Patient steered to lower-cost NCI-designated center
•Outcomes equivalent, saved $85K (18%)
•Established preferred CAR-T network for future cases

Quantify Your Multi-Million Dollar Gene Therapy Risk

Screen your population for gene therapy eligibility across 18 indications. Model FDA pipeline approvals. Get stop-loss laser recommendations before the $2M claim hits.

Run Exposure Analysis→